Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C

Liver International

Volumn 37, Issue 8, 2017, Pages 1122-1127

  Virlogeux, Victor ^a,b   Pradat, Pierre ^a,b   Hartig Lavie, Kerstin ^a,b   Bailly, François ^a,b   Maynard, Marianne ^a,b   Ouziel, Guillaume ^a,b   Poinsot, Domitille ^a,b   Lebossé, Fanny ^a,b   Ecochard, Marie ^a,b   Radenne, Sylvie ^a,b   Benmakhlouf, Samir ^a,b   Koffi, Joseph ^a,b   Lack, Philippe ^a,b   Scholtes, Caroline ^a,b   Uhres, Anne Claire ^a   Ducerf, Christian ^a,b   Mabrut, Jean Yves ^a,b   Rode, Agnès ^a   Levrero, Massimo ^a,b   Combet, Christophe ^b   Merle, Philippe ^a,b   Zoulim, Fabien ^a,b   more..

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

direct acting antivirals; hepatitis C virus; hepatocellular carcinoma; recurrence

Indexed keywords

DACLATASVIR; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC HEPATITIS C; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RECURRENCE RISK; TREATMENT DURATION; AGED; COMPLICATION; LIVER TUMOR; RETROSPECTIVE STUDY; SECONDARY PREVENTION; VERY ELDERLY; VIROLOGY;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SECONDARY PREVENTION;

EID: 85019654060     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13456     Document Type: Article

References (19)

1. El-Serag HB. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology. 2012;142:1264-1273 e1.
2. Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1. Gut. 2015;64:1824-1833.
3. van der Meer AJ, Wedemeyer H, Feld JJ, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312:1927-1928.
4. Carrat F. Clinical outcomes in HCV-infected patients treated with direct acting antiviral - 18-month post-treatment follow-up in the French ANRS CO22 HEPATHER Cohort study - EASL 2016. J Hepatol. 2016;64:S213-S424.
5. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726.
6. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734-740.
7. Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol. 2016;65:856-858.
8. Conti F, Buonfiglioli F, Scuteri A, et al. Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals. J Hepatol. 2016;65:727-733.
9. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
10. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
11. Recommendations AFEF sur la prise en charge des hepatites virales C [Internet]. 2016 [cited 2016 Jun 20]; at http://www.afef.asso.fr/ckfinder/userfiles/files/recommandations-textes-officiels/Recoavril2016.pdf Accessed 16 May, 2017.
12. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236.
13. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
14. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344.
15. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344-1354.
16. Cabibbo G, Petta S, Barbàra M, et al. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017; 37:1157-1166.
17. Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol. 2016;65:861-862.
18. Trinchet J-C, Bourcier V, Chaffaut C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology. 2015;62:737-750.
19. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329-337.